AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 8,404 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 8,404 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total value of $546,260.00. Following the sale, the insider directly owned 134,341 shares of the company’s stock, valued at $8,732,165. This represents a 5.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 23rd, Salvatore Privitera sold 4,519 shares of AtriCure stock. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00.
• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Stock Performance

NASDAQ ATRC opened at $61.28 on Friday. The stock has a market cap of $3.12 billion, a PE ratio of 159.83 and a beta of 1.23. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.19 and a current ratio of 4.33. The firm has a 50-day moving average of $56.62 and a 200-day moving average of $38.63. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $66.02.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. The business had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. AtriCure had a net margin of 2.52% and a return on equity of 4.01%. On average, sell-side analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current year.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
• Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
• Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
• Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
• Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing

Hedge Funds Weigh In On AtriCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp increased its stake in shares of AtriCure by 488.6% in the 3rd quarter. Fifth Third Bancorp now owns 11,543 shares of the medical device company’s stock valued at $649,000 after purchasing an additional 9,582 shares during the last quarter. Maryland State Retirement & Pension System acquired a new position in shares of AtriCure during the 3rd quarter worth $639,000. Lisanti Capital Growth LLC acquired a new position in shares of AtriCure during the 3rd quarter worth $4,460,000. Fulcrum Asset Management LLP bought a new stake in shares of AtriCure during the 3rd quarter worth $92,000. Finally, Brighton Jones LLC bought a new stake in shares of AtriCure during the 3rd quarter worth $279,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ATRC. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Wednesday, October 21st. Needham & Company LLC boosted their price objective on shares of AtriCure from $64.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of AtriCure from $36.00 to $62.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Citizens Jmp increased their target price on shares of AtriCure from $52.00 to $68.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $61.80.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.